On February 19, 2026, Pulse Biosciences, Inc. entered a Sales Agreement with TD Securities to potentially sell up to $59,976,196 worth of common stock, while terminating a previous equity distribution agreement on February 18, 2026. This deal allows for flexible sales based on market conditions and company discretion.